Top Page
China Health Group
(0673)
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
China Health Group Business Overview & Revenue Model
China Health Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.27M | 38.94M | 59.93M | 76.41M | 107.03M | 87.89M |
| Gross Profit | 8.52M | 9.23M | 13.64M | 27.19M | 28.69M | 25.99M |
| EBITDA | -36.03M | -63.71M | -37.42M | -29.04M | -4.38M | -1.47M |
| Net Income | -42.51M | -67.79M | -40.19M | -42.05M | -12.21M | -7.74M |
Balance Sheet | ||||||
| Total Assets | 187.16M | 147.35M | 192.32M | 221.19M | 225.96M | 217.82M |
| Cash, Cash Equivalents and Short-Term Investments | 2.41M | 1.05M | 4.01M | 11.48M | 8.54M | 4.59M |
| Total Debt | 5.54M | 6.50M | 5.66M | 6.04M | 18.47M | 5.36M |
| Total Liabilities | 135.74M | 147.25M | 132.56M | 127.23M | 140.82M | 117.83M |
| Stockholders Equity | 43.94M | -7.66M | 52.04M | 86.33M | 79.58M | 95.04M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -8.35M | -7.03M | -9.59M | 31.00M | -10.90M |
| Operating Cash Flow | -3.05M | -6.76M | -6.40M | -8.22M | 31.80M | -9.06M |
| Investing Cash Flow | 190.00K | -1.58M | -301.00K | -5.40M | -35.29M | -1.84M |
| Financing Cash Flow | 1.46M | 8.79M | -1.24M | 27.66M | 12.96M | 2.63M |
China Health Group Technical Analysis
China Health Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$294.99M | ― | -305.54% | ― | -35.02% | -64.05% | |
51 Neutral | $7.85B | -0.21 | -41.41% | 2.22% | 22.81% | -2.01% | |
| ― | $8.75B | 6.93 | 8.35% | 3.33% | ― | ― | |
| ― | $7.47B | 8.00 | 8.74% | 3.89% | ― | ― | |
75 Outperform | HK$15.71B | 51.32 | 7.40% | 0.95% | 0.67% | -1.75% | |
48 Neutral | HK$952.29M | ― | -31.49% | ― | -7.28% | -46.18% | |
| ― | HK$629.64M | 10.90 | 8.78% | 8.39% | ― | ― |
China Health Group Corporate Events
China Health Group Limited, a company incorporated in Bermuda and operating in Hong Kong, has announced a special general meeting to approve two conditional subscription agreements. The agreements involve the issuance of new shares to Ample Colour Limited and Perfect Link Group Limited, raising a total of HK$60,000,000. This strategic move aims to strengthen the company’s capital base and enhance its market position.
China Health Group Limited has announced the dispatch of a circular related to a proposal, which includes recommendations from the Independent Board Committee and advice from an Independent Financial Adviser. The circular will be sent to shareholders on July 31, 2025. The announcement also includes a revised timetable for the proposal, detailing important dates for shareholder meetings and the rights issue, which could impact shareholder engagement and the company’s market activities.
China Health Group Limited has announced its annual general meeting scheduled for September 26, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, and approval for the board to appoint additional directors and fix their remuneration. Additionally, the meeting will consider authorizing the directors to allot and issue shares, with certain limitations, which could impact the company’s capital structure and shareholder value.
China Health Group Limited has completed the implementation of remedial actions following an internal control review to ensure compliance with Hong Kong Stock Exchange Listing Rules. The follow-up review, completed by an IC Consultant, confirmed that the company has strengthened its compliance manuals and integrated various policies, including those related to notifiable transactions and financial information disclosure, to address key findings from the initial review.
China Health Group Limited has announced the completion of a significant transaction involving the settlement deed for acquiring Jinmei Developments Limited. As a result of fulfilling the condition precedent, the company has canceled a promissory note worth HK$146 million, transferred Long Heng’s entire equity interest to the noteholder, and issued a settlement note of HK$12 million. This transaction results in Jinmei Developments Limited and its subsidiaries ceasing to be subsidiaries of China Health Group, potentially impacting the company’s operational structure and market positioning.
China Health Group Limited has announced a further delay in the dispatch of a circular related to its capital raising proposal, which includes new share subscriptions, a proposed rights issue, and connected transactions. The delay is due to the need for additional time to finalize certain financial information and advice letters. The company has applied for an extension to the deadline for dispatching the circular, now expected on or before July 31, 2025. This delay may affect the expected timetable for the proposal, and further announcements will be made as necessary.
China Health Group Limited announced its final results for the year ended 31 March 2025, reporting a significant decrease in revenue from HK$59,930,000 in 2024 to HK$38,943,000 in 2025. The company also experienced an increase in its operating loss, rising from HK$41,967,000 in 2024 to HK$67,126,000 in 2025, which has implications for its financial stability and market positioning. The resumption of trading of the company’s shares may impact stakeholders’ confidence and the company’s future market activities.
China Health Group Limited, through its wholly-owned subsidiary Long Heng, has entered into a Settlement Deed to address financial disputes triggered by a Cross-Default Clause. The company will transfer its entire equity interest in a target entity to a noteholder and issue a Settlement Note to resolve these disputes, resulting in the target entity no longer being a subsidiary. The company plans to use proceeds from a proposed capital raising to repay the Settlement Note, with additional funds allocated to settle various payables and improve cash flow management, aiming to restore long-term financial stability.
China Health Group Limited has announced a suspension of trading in its shares on the Hong Kong Stock Exchange. This suspension, effective from July 2, 2025, is due to a delay in the publication of the company’s audited annual results for the year ending March 31, 2025. The company plans to release further announcements as necessary, in compliance with the stock exchange’s regulations.
China Health Group Limited, listed on the Hong Kong Stock Exchange, has announced a delay in the publication of its annual results for the year ending March 31, 2025. This delay is due to additional time needed to address requests from auditors for legal confirmations and settlement arrangements. Consequently, the board meeting to approve these results has been postponed, and trading of the company’s shares will be suspended starting July 2, 2025, until the results are published on July 4, 2025. The company advises shareholders and potential investors to exercise caution.
China Health Group Limited announced the lapse of its major transaction involving the acquisition of 100% equity interest in ProteinT (Tianjin) Diagnostic, Co., Ltd. due to unfulfilled conditions by the extended deadline. The termination of the agreement is not expected to have a material adverse impact on the company’s existing business, operations, or financial position.
China Health Group Limited has issued a profit warning for the fiscal year ending March 31, 2025, anticipating a net loss between HK$66 million and HK$70 million, compared to a HK$40.2 million loss in the previous year. The increased loss is attributed to a US$4 million litigation expense following a court judgment, a reduction in other income due to less reversal of payables, and a decrease in gross profit. These factors were partially offset by reduced selling, distribution, and administrative costs.
China Health Group Limited has announced a board meeting scheduled for June 30, 2025, to consider and approve the company’s final results for the fiscal year ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder interests.
China Health Group Limited has announced a delay in the dispatch of a circular related to several financial and strategic initiatives, including subscriptions of new shares, a proposed rights issue, and connected transactions. The delay is due to the need for additional time to finalize financial information and obtain necessary approvals, with the new deadline set for on or before July 11, 2025. This extension is intended to ensure that shareholders have access to updated financial data, allowing them to make informed decisions regarding the proposals.
China Health Group Limited has undertaken an internal control review to enhance its compliance with the Hong Kong Stock Exchange’s listing rules. The company engaged PRO-WIS Risk Advisory Services Limited to conduct a thorough review of its internal control systems from April 2024 to March 2025. The review aimed to ensure effective compliance with the listing rules, including discussions with management and employees and identifying areas for improvement. The board considers the consultancy firm well-qualified for this task, given its extensive experience in internal controls and corporate governance across various sectors.
China Health Group Limited has announced a series of financial initiatives to address its financial challenges and support future growth. The company plans to issue 700 million new shares through subscriptions and a rights issue, representing a significant increase in its share capital. These measures are aimed at bolstering the company’s financial position and ensuring the continuation of its operations.